Daily diabetes pills are changing treatment as pharmaceutical developers make new developments, Starnieuws reported.
Diabetes and obesity treatments are changing as GLP-1 group medicines, previously known mainly as weekly injections, increasingly become available in tablet form, according to Al Jazeera.
Global diabetes cases among adults reached 589 million, affecting about one in nine adults aged 20 to 79 according to the International Diabetes Federation. Suriname accounts for an estimated 53,200 adult cases, representing a 13.8 percent prevalence rate across the population.
This development is particularly relevant for countries in the Global South, where diabetes is a growing health problem. The new generation of daily pills can make treatment more accessible, especially in developing countries where costs, limited health facilities, and cold-storage problems form an obstacle.
New Regulatory Approvals
The US Food and Drug Administration approved a tablet form of semaglutide under the brand name Wegovy in December 2025 for weight management in adults with obesity or overweight conditions.
A second daily GLP-1 tablet called Foundayo, developed by Eli Lilly, received FDA approval on April 1, 2026. The European Medicines Agency issued a positive opinion for the drug on October 15, 2026, ahead of Chinese authorities granting approval to Eli Lilly on November 12, 2026. That advice forms an important step toward market authorization in the European Union.
High costs limit access to GLP-1 treatments
High costs continue to limit patient access across developing nations and low-income regions. The World Health Organization published guidelines in December 2025 recommending GLP-1 treatments for long-term obesity care while warning that steep prices threaten health equity. Injectable GLP-1 medicines are expensive in many countries and are not universally covered by insurance or health programs.
How oral GLP-1 medications work and what makes Foundayo different
How do oral GLP-1 medications work in the body?
GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the body that plays a role in regulating blood sugar levels and appetite. The medicines mimic the action of this hormone, stimulating the pancreas to release insulin when blood sugar levels rise, slowing stomach emptying, and reducing the feeling of hunger. This allows them to help regulate type 2 diabetes and reduce body weight.
What makes Foundayo different from earlier oral treatments?
Foundayo can be taken at any time of day without food or water restrictions, unlike oral semaglutide which requires strict innamerichtlijnen.
Are lifestyle changes still necessary while taking these pills?
Health experts emphasize that medications cannot replace proper nutrition, regular physical activity, and ongoing medical supervision.
Worth a look